Nishank Jain
Associate Professor
faculty
Internal Med, College of Medicine
Research Areas
Biography and Research Information
OverviewAI-generated summary
Nishank Jain, MD, MPH, is an Associate Professor in the Department of Medicine at the University of Arkansas for Medical Sciences. His clinical and research work focuses on nephrology, with a particular interest in the role of platelets in chronic kidney disease (CKD) pathophysiology and the application of antiplatelet agents in patients with kidney diseases. He has received funding from the American Heart Association (AHA), an institutional KL2 grant, and career development grants from the American Society of Nephrology and the AHA to support his research endeavors.
Dr. Jain leads a research group and has collaborated with researchers at the University of Arkansas for Medical Sciences, including Jerry Ware, Jawahar L. Mehta, Adam Corken, and Otis M. Davis. His scholarly output includes 61 publications with over 1,200 citations and an h-index of 17. His recent publications explore topics such as the role of platelets in CKD, updates on novel therapies for CKD patients, and comparative effectiveness studies of oral P2Y12 inhibitors in patients undergoing chronic dialysis.
Beyond his research, Dr. Jain is committed to medical education. He actively engages in training medical students, aiming to foster their interest in academic medicine and has received teaching awards for his efforts. He also facilitates opportunities for medical students to present their research at national meetings.
Research Overview
Nishank Jain, MD, MPH, is a nephrologist and an Associate Professor in the Department of Medicine at University of Arkansas for Medical Sciences, Little Rock, AR. He completed his clinical and research fellowship at UT Southwestern Medical Center, Dallas, TX, before joining as a faculty member. His research interest is in the role of platelets in CKD pathophysiology and use of antiplatelet agents in patients with kidney diseases. He has been funded by post-doctoral fellowship grant from the American Heart Association (AHA), institutional KL2 grant and career development grants from the American Society of Nephrology and the AHA. Dr. Jain is passionate about education and is driven by training and engaging medical students for a career in academic medicine. He has also helped medical students receive Honors in Research upon graduation. Dr. Jain has received medical student teaching awards. He has also engaged in SSCI activities by sending medical students to present original research work at the Annual Meetings.
Metrics
- h-index: 17
- Publications: 63
- Citations: 1,230
Selected Publications
-
Fungal DNA in Circulation (2025)
-
AKI in Patients Receiving Chimeric Antigen Receptor T Cells: Risk Factors and Characteristics (2025)
-
Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients (2025)
-
Sepsis-Related Hospitalization and Mortality in Patients with CKD (2025)
-
Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation (2025)
-
Potent P2Y12 Receptor Inhibitors Reduce Risk for Hospitalization from Sepsis in Patients with CKD (2025)
-
Higher Glycolysis in Circulating Leukocytes in Patients with CKD (2024)
-
Platelets, inflammation, and purinergic receptors in chronic kidney disease (2024)
-
P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis (2024)
-
EFFICACY AND OUTCOMES OF LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH ATRIAL FIBRILLATION AND ESRD (2024)
-
Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD] (2024)
-
Authors' Reply: Platelet Count, Platelet Volume and CKD (2024)
-
Renal Biomarkers in Heart Failure (2024)
-
Use of Antiplatelet Drugs Targeting Platelet P2Y12 Receptor Is Associated with Reduced Risk for Infectious Death in Veterans with CKD (2023)
-
Depression and Other Psychological Issues in CKD (2023)
Grants & Funding
- Glycolysis in Leukocytes and Inflammation in Patients with CKD Dialysis Clinic, Inc. Principal Investigator
- Platelet, Inflammation and Thrombosis in Chronic Kidney Disease NIH/NCATS Principle Investigator
- Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease Dialysis Clinic, Inc. Principal Investigator
- Glycolysis in Leukocytes and Inflammation in Patients with CKD Dialysis Clinic, Inc. Principal Investigator
- Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease Dialysis Clinic, Inc. Principal Investigator
- Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease Dialysis Clinic, Inc. Principal Investigator
- Effectiveness and safety of clopidogrel, prasugrel and ticagrelor in patients with end stage renal disease (ESCALATE) American Heart Association Principal Investigator
- Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease Dialysis Clinic, Inc. Principal Investigator
Collaboration Network
Top Collaborators
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
Showing 5 of 9 shared publications
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- Abstract 12562: Prasugrel May Be Associated With All-Cause Mortality Benefit in Patients on Chronic Dialysis
Showing 5 of 7 shared publications
- Role of Platelets in Chronic Kidney Disease
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- 438 Platelets, Inflammation and Thrombosis in Chronic Kidney Disease
Showing 5 of 6 shared publications
- Role of Platelets in Chronic Kidney Disease
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Authors' Reply: Platelet Count, Platelet Volume and CKD
Showing 5 of 6 shared publications
- Updates on New Therapies for Patients with CKD
- Platelets, inflammation, and purinergic receptors in chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Authors' Reply: Platelet Count, Platelet Volume and CKD
- 564 Platelets and Leukocytes Interact to Modulate Inflammation in Patients with CKD
Showing 5 of 6 shared publications
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Screening for Cardiovascular Disease in CKD: PRO
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- Depression and Other Psychological Issues in CKD
- Updates on New Therapies for Patients with CKD
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- 438 Platelets, Inflammation and Thrombosis in Chronic Kidney Disease
- Role of Platelets in Chronic Kidney Disease
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Platelets, inflammation, and purinergic receptors in chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Role of Platelets in Chronic Kidney Disease
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Abstract 12562: Prasugrel May Be Associated With All-Cause Mortality Benefit in Patients on Chronic Dialysis
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Platelet Count and Platelet Volume in Patients with CKD
- Renal Biomarkers in Heart Failure
- Abstract 12562: Prasugrel May Be Associated With All-Cause Mortality Benefit in Patients on Chronic Dialysis
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- Abstract 12562: Prasugrel May Be Associated With All-Cause Mortality Benefit in Patients on Chronic Dialysis
- P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD]
- Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Aggregation in Patients With Stages 4-5 CKD
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation
- P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Higher Glycolysis in Circulating Leukocytes in Patients with CKD
Similar Researchers
Based on overlapping research topics